Second Generation" Drug-Eluting Stents Implantation Followed by Six Versus Twelve-Month - Dual Antiplatelet Therapy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00944333|
Recruitment Status : Terminated (STOP due to recent data in literature questioning the need to continue DAP beyond six months in patients with stable coronary artery stenting with DES.)
First Posted : July 23, 2009
Last Update Posted : August 5, 2014
Prospective, randomized, non-inferiority, multicenter, international study.In total 4000 patients (70 centers in Europe) with de novo lesions in native coronary arteries who meet the eligibility criteria randomized to 6 versus 12 month dual antiplatelet therapies following a second generation DES implantation.
Assuming that the true proportion of thrombotic events is equal to 2.3% for both regimens (6-month and 12-month clopidogrel) 2000 patients for each treatment group are necessary to demonstrate a non-inferiority of the 6-months regimen if the proportion of thrombotic events will be no more than 3.5% with a power of 0.80 and a significance level of 0.05 (one-tail).
If the non-inferiority hypothesis will be rejected, the superiority hypothesis (12-months regimen is superior to the 6-months-regimen) will be tested at a significance level of 0.05 (two-tails).
The maximal not clinically relevant difference for the non-inferiority hypothesis of 1.2 % more thrombotic events has to be considered together with the lower expected number of bleeding events in the 6-months regimen.
All the analysis will be done as "intention-to-treat" analysis.
|Condition or disease||Intervention/treatment||Phase|
|Angina Pectoris Silent Ischemia||Drug: Clopidogrel||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||1378 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Second Generation" Drug-Eluting Stents Implantation Followed by Six Versus Twelve-Month - Dual Antiplatelet Therapy|
|Study Start Date :||July 2009|
|Actual Primary Completion Date :||June 2014|
|Actual Study Completion Date :||July 2014|
Experimental: Clopidogrel 6
6 month dual antiplatelet therapies in patients after second generation DES implantation
300-600 loading dose 75 mg/die for 6 months
Experimental: Clopidogrel 12
12 month dual antiplatelet therapies in patients after second generation DES implantation
300-600 loading dose 75 mg/die for 12 months
- Definite and/or probable stent thrombosis occurring between 6 and 24 months [ Time Frame: 24 months ]
- Composite of major adverse cardiac events (MACE) defined as the occurrence at 24 months of cardiac death, or myocardial infarction, or urgent target vessel revascularization (cardiac bypass surgery, or repeat PTCA) [ Time Frame: 24 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00944333
|Irccs Fondazione Centro S. Raffaele Del Monte Tabor -|
|Milano (mi), Italy, 20132|